ESTRO 2025 - Abstract Book

S110

Invited Speaker

ESTRO 2025

these evidence-to-practice gaps, and potential impacts on vulnerable populations. Dissemination and implementation is a scientific discipline focused on using a systematic approach to developing and testing strategies that address barriers and leverage facilitators to practice change. An important consideration is aligning interventions with the “level” at which barriers exist, broadly defined as the health system, organization or clinic, clinician, patient, and characteristics of the intervention itself. In this presentation, we define key concepts and frameworks in implementation science (i.e. Proctor et al, the Consolidated Framework for Implementation Research) and review common study designs, including hybrid implementation-effectiveness trials and cluster randomization. We briefly discuss the interaction with related disciplines such as quality improvement and behavioral economics. Importantly, we highlight examples of studies evaluating implementation in radiation oncology, including changing defaults, audit and feedback, and patient-reported outcomes in routine care. We also discuss applications of implementation science frameworks to more traditional clinical trial designs, and opportunities to better inform and target efforts to promote clinical trial enrollment. Ultimately, this presentation aims to illustrate how trials of clinical implementation can promote quality and efficiency in cancer care through the development of effective, scalable, and sustainable care delivery solutions.

4828

Speaker Abstracts Patients as partners for guiding cancer care Erik A Briers Vice-Chairman, Europa Uomo, Antwerp, Belgium

Abstract: Estro 2025

Patients as partners for guiding cancer care

Dr Erik Briers MS PhD Vice-Chairman Europa Uomo Expert Patient Advocate

Patients are, should be, at the centre of medical care and everything should be directed to “serve” the patient. The patient should not only benefit from the treatment that the department provides, but also from her or his stay in your department. A patient presents herself or himself with a medical problem, you can be called in for help in an early stage or in a late more progressed stage. Both require a specific approach towards the patient. In prostate cancer as in all cancers we see the cancer journey for the patient can go through different stages which all ask for adapted solutions. In localized or locally advanced prostate cancer your role can be curative whare in metastasized prostate cancer good control over the progression of the disease is the objective. But in all treatments the balance between benefits and risks is crucial. Quality of life (with cancer) is central, and it is the result of high benefits (if possible) and low risks (if possible). But the definition of good, optimal quality of life is personal. It can be approached by talking with the patient and learning as much of her or his preferences and desires as possible. On the other hand, the clinician should inform the patient maximally on the treatment and its benefits and risks because it is the patient who will ultimately decide on the treatment. Thos process where the clinician shares all possible information on the disease and treatment and the patient on her or his personal preferences and wishes will end in “shared decision making” and should result in minimal decision regret after the treatment and the suffered side effects.